Shogo Nomura

Targeted Disruption of Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts

Toshihisa Komori, Hideshi Yagi, Shogo Nomura et al. · Cell · 1997 · 4.2K citations · Full text

Medicine, Developmental Biology, Orthopedic Surgery +16

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization

Shogo Nomura, A J Wills, JK Heath et al. · The Journal of Cell Biology · 1988 · 520 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +13

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine · 2016 · 295 citations

Medicine, Oncology, Pharmacotherapy +9

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura et al. · The Lancet Oncology · 2020 · 270 citations

Medicine, Oncology, Pharmacology +14